
RECEIVED CENTRAL FAX CENTER JUN 3 0 2005

FAX





GlaxoSmithKilne PO Box 13398 Five Moore Drive Research Triangle Park North Cerolina 27709

Tel: 919 483 2100 www.gsk.com

Attached:

- 1. Transmittal Form
- 2. Response to Restriction Requirement
- 3. Preliminary Amendment

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissernination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Doc Under the Pape	rwork Reduction Act of 1995,	no persons are required	U.S. Pale d to respond to a collecti		VED 10:5041 (05-04) VED 10	
TRANSMITTAL FORM			Application Num	ber	10/600,751	
			Filing Date		6/20/2003	
			First Named Inve	entor	Randy K. BLEDSOE	
			Art Unit		1652	
(to be used for all correspondence after initial filing)			Examiner Name		David J. Steadman	
Total Number of Peges In This Submission			Attorney Docket	Number	PU4803US	
ENCLOSURES (Check all that apply)						
Fee Transm	ittal Form	Drawing((s)		After Allowance Communication to TC	
Fee	Attached	Licensing	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendmen	t / Reply	Patition][Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
Afler Final Petil			o Convert to a al Application		Proprietary Information	
Affi	davits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address		doress	Status Letter	
Extension of Time Request		Terminal Disclaimer		[Other Enclosure(s) (please identify below):	
Express Abandonment Request		Request for Refund		ł		
Information Disclosure Statement		CD, Number of CD(s)		_		
Certified Copy of Priority			Landscape Table on CD			
Document(s)		Remarks	j			
Incomplete	o Missing Parts/ Application	Annlingnte believ	Applicants believe that no fee is required for this submission. However, the			
	ly to Missing Parts under CFR 1.52 or 1,53	Commissioner is hereby authorized to charge any feet required or credit any overpayment to Deposit Account No. 07-1392.				
	SIGNATUS	E OF ARRIVAN	ATTORNEY O	D AGENT		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name GlaxoSinitbKline						
Signature Kothyn L. Coult						
Printed name Kathryn L. Coulter						
Dato	June 30, 2005			Reg. No. 4	5,889	
		DTYPIO ATE CE	TDANIO	100-0		
I hereby certify that to sufficient postage as date shown below:	his correspondence la beli	no faccimila transmit	TRANSMISSION ted to the USPTO or Commissioner for Pat	والمرائد ومراد	th the United States Postal Service with x 1450, Alexandris, VA 22313-1450 on the	
Signature	(77.	0				
Typed or printed nam	ne Johnie Jones	Jones	<u>/</u>	Date	June 30, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

June 30, 2005

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Atty. Docket No.:PU4631US

RECEIVED **CENTRAL FAX CENTER** JUN 3 0 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Bledsoe et al.

Application No.:

10/600,751

Confirmation No.

5089

Filed:

June 20, 2003

Art Unit:

1652

Examiner:

David J. Steadman

STRUCTURE OF A GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN COMPRISING AN EXPANDED BINDING POCKET AND

METHODS EMPLOYING SAME

Customer No.:

23347

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Sir:

Please amend the above-referenced application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.